RU2556340C2 - Композиция инсулина длительного действия - Google Patents

Композиция инсулина длительного действия Download PDF

Info

Publication number
RU2556340C2
RU2556340C2 RU2012107487/15A RU2012107487A RU2556340C2 RU 2556340 C2 RU2556340 C2 RU 2556340C2 RU 2012107487/15 A RU2012107487/15 A RU 2012107487/15A RU 2012107487 A RU2012107487 A RU 2012107487A RU 2556340 C2 RU2556340 C2 RU 2556340C2
Authority
RU
Russia
Prior art keywords
insulin
compound
hydrogel
mmol
composition according
Prior art date
Application number
RU2012107487/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2012107487A (ru
Inventor
Кеннетт СПРОГЕЕ
Феликс КЛЕЕМАНН
Ульрих ХЕРЗЕЛЬ
Сильвия КАДЕН-ФАГТ
Торбен ЛЕССМАНН
Харальд РАУ
Томас ВЕГГЕ
Original Assignee
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх
Publication of RU2012107487A publication Critical patent/RU2012107487A/ru
Application granted granted Critical
Publication of RU2556340C2 publication Critical patent/RU2556340C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
RU2012107487/15A 2009-07-31 2010-07-30 Композиция инсулина длительного действия RU2556340C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP09167017 2009-07-31
EP09167017.4 2009-07-31
EP09179337 2009-12-15
EP09179337.2 2009-12-15
EP09179827 2009-12-18
EP09179827.2 2009-12-18
PCT/EP2010/061160 WO2011012719A1 (en) 2009-07-31 2010-07-30 Long acting insulin composition

Publications (2)

Publication Number Publication Date
RU2012107487A RU2012107487A (ru) 2013-09-10
RU2556340C2 true RU2556340C2 (ru) 2015-07-10

Family

ID=43033453

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012107487/15A RU2556340C2 (ru) 2009-07-31 2010-07-30 Композиция инсулина длительного действия

Country Status (29)

Country Link
US (1) US9265723B2 (es)
EP (1) EP2459171B1 (es)
JP (1) JP5732053B2 (es)
KR (1) KR101759499B1 (es)
CN (1) CN102625695B (es)
AU (1) AU2010277560B2 (es)
BR (1) BR112012001988A2 (es)
CA (1) CA2769540C (es)
CL (1) CL2012000469A1 (es)
CO (1) CO6491085A2 (es)
CR (1) CR20120019A (es)
DK (1) DK2459171T3 (es)
EC (1) ECSP12011631A (es)
ES (1) ES2636741T3 (es)
GT (1) GT201200020A (es)
IL (1) IL217613A (es)
MA (1) MA33466B1 (es)
MX (1) MX2012001141A (es)
NI (1) NI201200013A (es)
NZ (1) NZ597964A (es)
PE (1) PE20121170A1 (es)
PL (1) PL2459171T3 (es)
PT (1) PT2459171T (es)
RU (1) RU2556340C2 (es)
SG (1) SG178195A1 (es)
TN (1) TN2012000010A1 (es)
UA (1) UA108475C2 (es)
WO (1) WO2011012719A1 (es)
ZA (1) ZA201200224B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2741524T3 (es) * 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
ES2636741T3 (es) 2009-07-31 2017-10-09 Sanofi-Aventis Deutschland Gmbh Composición de insulina de acción prolongada
MA33467B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Promédicaments comprenant un conjugué insuline-lieur
PL2498801T3 (pl) 2009-11-13 2018-08-31 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
AU2012216648C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
BR112014012789A2 (pt) * 2011-11-28 2019-09-24 Phasebio Pharmaceuticals Inc agentes terapêuticos compreendendo sequências de aminoácidos de insulina
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
MY181626A (en) 2013-04-03 2020-12-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
CA2934538C (en) * 2013-12-18 2023-03-14 Windgap Medical, Inc. Drug mixing and delivery system and method
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR20160104724A (ko) * 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
JP2020114861A (ja) * 2014-01-09 2020-07-30 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
CN114939156A (zh) * 2014-01-09 2022-08-26 赛诺菲 门冬胰岛素的稳定化药物制剂
JP7173953B2 (ja) * 2014-01-09 2022-11-16 サノフイ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
AU2015364280A1 (en) 2014-12-18 2017-07-06 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
CN105796508A (zh) * 2014-12-30 2016-07-27 江苏万邦生化医药股份有限公司 甘精胰岛素缓释微球、甘精胰岛素微球注射剂及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MX2018009938A (es) 2016-03-01 2019-03-14 Ascendis Pharma Bone Diseases As Profarmacos de hormona paratiroidea (pth).
WO2018057977A1 (en) 2016-09-23 2018-03-29 Delpor, Inc. Stable compositions for incretin mimetic compounds
DK3518961T3 (da) 2016-09-29 2023-04-24 Ascendis Pharma Bone Diseases As PTH-forbindelser med lave forhold mellem top og bund
CA3037442A1 (en) * 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
US10869851B1 (en) * 2017-03-13 2020-12-22 The United States Government As Represented By The Secretary Of The Army Targeting NUR77 for mitigating perinatal neuroinflammation
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2019038412A1 (en) 2017-08-24 2019-02-28 Novo Nordisk A/S GLP-1 COMPOSITIONS AND USES THEREOF
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
AU2021207313A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
BR9306038A (pt) 1992-02-28 1998-01-13 Univ Texas Hidrogéis biodegradáveis fotopolimerizáveis como materiais de contato de tecidos e condutores de liberação controlada
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE19626762A1 (de) 1996-07-03 1998-01-08 Basf Ag Enzymatisch spaltbare Linker für Festphasensynthesen
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1032587B2 (en) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
AU1825299A (en) 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
ATE255422T1 (de) 1998-01-07 2003-12-15 Debio Rech Pharma Sa Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
JP2002527408A (ja) 1998-10-09 2002-08-27 ミシガン大学 ドラッグデリバリー用ヒドロゲル及び水溶性ポリマーキャリアー
WO2000033764A1 (en) 1998-12-04 2000-06-15 Pathak Chandrashekhar P Biocompatible crosslinked polymers
DK1181323T3 (da) 1999-02-01 2011-10-17 Eidgenoess Tech Hochschule Biomaterialer dannet med nukleofil additionsreaktion med konjugerede uimættede grupper
EP1105409B1 (en) 1999-05-17 2006-03-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1223986A2 (en) 1999-06-11 2002-07-24 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol)
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
KR20030009346A (ko) 2000-01-28 2003-01-29 인파임드테라퓨틱스, 잉크. 서방형 단백질 고분자
US6884778B2 (en) 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4841066B2 (ja) 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2002085419A2 (en) 2001-04-23 2002-10-31 Wisconsin Alumni Research Foundation Bifunctional-modified hydrogels
MY137181A (en) 2001-05-21 2009-01-30 Nektar Therapeutics Pulmonary administration of chemically modified insulin
EP1306127B2 (en) 2001-10-26 2011-09-07 OctoPlus PolyActive Sciences B.V. Method for the preparation of purified microparticles
US6960298B2 (en) 2001-12-10 2005-11-01 Nanogen, Inc. Mesoporous permeation layers for use on active electronic matrix devices
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
JP4527404B2 (ja) 2002-04-04 2010-08-18 エンゾン，インコーポレーテッド インドールのポリマー性アシル誘導体
DE10221457A1 (de) 2002-05-15 2003-11-27 Behr Gmbh & Co Wärmeübertrager und Verfahren zu seiner Herstellung
EP1531868A2 (en) 2002-06-03 2005-05-25 Alnis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
EP1529055A4 (en) 2002-06-10 2005-11-30 Merck & Co Inc INSULATED NUCLEIC ACID MOLECULE ENCODING A CENTROMER-ASSOCIATED MOTOR TYPE PROTEIN, AND USES THEREOF
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
JP5048332B2 (ja) 2003-05-23 2012-10-17 ネクター セラピューティクス 特定の原子配置を有するポリマー誘導体
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
EP1586334A1 (en) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006038462A1 (ja) 2004-10-01 2006-04-13 Kyushu University, National University Corporation 新規ステロイド産生細胞
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7407117B2 (en) 2004-10-28 2008-08-05 Meadwestvaco Calmar, Inc. Liquid sprayer assembly
JP2006163996A (ja) 2004-12-09 2006-06-22 Evolium Sas 行動履歴に基づくプッシュ型の情報提供システム
AU2005323534A1 (en) 2005-01-05 2006-07-13 Philip S. Portoghese Analgesic conjugates
KR100665672B1 (ko) 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US8070810B2 (en) 2006-01-12 2011-12-06 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
DE602006007679D1 (de) 2006-03-31 2009-08-20 Sony Deutschland Gmbh Verfahren zur Herstellung eines vernetzten Polymer-Gels
CA2653200A1 (en) 2006-05-25 2007-12-06 The General Hospital Corporation Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
AU2007296054B2 (en) 2006-09-15 2013-03-28 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
GB0619175D0 (en) 2006-09-29 2006-11-08 Univ Nottingham Polymer
CN101541857B (zh) 2006-11-27 2012-12-12 阿克塔马克斯手术器材有限责任公司 多官能聚环氧烷、水凝胶和组织粘合剂
JP2010519183A (ja) 2007-02-06 2010-06-03 インセプト エルエルシー 生理溶液の溶出のためのタンパク質の沈殿を用いる重合
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2008116913A2 (en) 2007-03-28 2008-10-02 Novo Nordisk A/S Peptide compounds with transient biodegradable pegylation
JP2010523243A (ja) 2007-04-13 2010-07-15 クロス・バイオサージェリー・アクチェンゲゼルシャフト 高分子組織シーラント
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
EP2164519A2 (en) * 2007-06-08 2010-03-24 Ascendis Pharma AS Long-acting polymeric prodrugs of exendin
JP5688969B2 (ja) * 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
AU2009214615B2 (en) 2008-02-13 2014-06-12 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
JP2011518881A (ja) 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド 片頭痛の治療のための製剤
SI3050576T1 (sl) 2008-04-29 2021-08-31 Ascendis Pharma Endocrinology Division A/S Spojine pegiliranega rekombinantnega humanega rastnega hormona
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs
ES2636741T3 (es) 2009-07-31 2017-10-09 Sanofi-Aventis Deutschland Gmbh Composición de insulina de acción prolongada
NZ597960A (en) 2009-07-31 2013-07-26 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
MA33467B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Promédicaments comprenant un conjugué insuline-lieur
EP2493514B1 (en) 2009-10-29 2018-08-22 Ascendis Pharma A/S Sterilization of biodegradable hydrogels
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ЭНЦИКЛОПЕДИЯ ЛЕКАРСТВ, Регистр Лекарственных Средств, Москва, РЛС, 2000, стр.368-373 *

Also Published As

Publication number Publication date
DK2459171T3 (en) 2017-09-25
GT201200020A (es) 2014-09-10
PL2459171T3 (pl) 2017-11-30
WO2011012719A1 (en) 2011-02-03
US9265723B2 (en) 2016-02-23
PE20121170A1 (es) 2012-09-10
SG178195A1 (en) 2012-03-29
ZA201200224B (en) 2012-09-26
AU2010277560B2 (en) 2014-12-11
EP2459171A1 (en) 2012-06-06
PT2459171T (pt) 2017-08-16
CR20120019A (es) 2012-03-02
JP2013500952A (ja) 2013-01-10
TN2012000010A1 (en) 2013-09-19
RU2012107487A (ru) 2013-09-10
KR101759499B1 (ko) 2017-07-19
MA33466B1 (fr) 2012-07-03
CN102625695A (zh) 2012-08-01
EP2459171B1 (en) 2017-06-21
NZ597964A (en) 2014-04-30
ECSP12011631A (es) 2012-02-29
NI201200013A (es) 2012-05-29
KR20120089261A (ko) 2012-08-09
IL217613A (en) 2016-08-31
ES2636741T3 (es) 2017-10-09
BR112012001988A2 (pt) 2017-05-09
AU2010277560A1 (en) 2012-02-23
CO6491085A2 (es) 2012-07-31
CN102625695B (zh) 2015-05-27
CA2769540A1 (en) 2011-02-03
MX2012001141A (es) 2012-03-29
US20120183616A1 (en) 2012-07-19
JP5732053B2 (ja) 2015-06-10
CL2012000469A1 (es) 2012-10-19
CA2769540C (en) 2017-08-15
UA108475C2 (uk) 2015-05-12

Similar Documents

Publication Publication Date Title
RU2556340C2 (ru) Композиция инсулина длительного действия
US9457066B2 (en) Prodrugs comprising an insulin linker conjugate
RU2593774C2 (ru) Пролекарства, содержащие конъюгат эксендин-линкер
RU2574667C2 (ru) Пролекарства, содержащие конъюгат инсулина и линкера
TW201300131A (zh) 包含艾塞那肽（ｅｘｅｎｄｉｎ）連接子接合物之前藥

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180731